Vial Seal Batch Traceability: Lot Control and Documentation

Batch traceability for a vial seal is the documented ability to work backwards from any packed carton to the aluminium coil, polymer, lacquer and ink lots it was made from, the line, tooling and shift that made it, and the inspection records that released it, and to work forwards from any raw-material lot to every customer that received seals containing it. It is a requirement on the supplier under ISO 15378:2017 and a requirement on the drug manufacturer under 21 CFR Part 211 and EU GMP. When something goes wrong, traceability is what decides whether the response is a handful of pallets or an entire year of supply.

This guide sets out what a seal batch is, what has to be traceable, the documents that travel with a lot, what the standards require on each side, and how the chain is used during an investigation.

Key takeaways

Traceability runs in two directions: backwards from a finished carton to its inputs, and forwards from an input lot to every delivery it reached.
A seal’s traceable inputs include the aluminium coil lot, the polymer and masterbatch lots, and the lacquer and ink lots, plus the press, tooling, line and shift.
ISO 15378:2017 applies GMP requirements to primary packaging manufacture on top of ISO 9001:2015, whose clause 8.5.2 covers identification and traceability.
On the customer’s side, 21 CFR 211.184 requires records that allow any batch of drug product to be linked to the container and closure lots used in it, with a reconciliation of each lot’s use.
Under 21 CFR 211.84, each incoming lot of containers and closures is held from use until sampled, examined and released by the quality unit.
The documents that normally accompany a seal lot are a certificate of analysis or conformance, a packing list, lot-marked cartons, and, where the supplier holds one, a reference to its Type III Drug Master File.
Traceability is only as good as its narrowest bracket. Large, loosely defined lots make every investigation more expensive.

What a “batch” means for a vial seal

A seal batch or lot is a defined quantity of seals produced under uniform conditions, given a single identifier that is printed on every carton it is packed into. The definition is set by the manufacturer and written into the quality system: it might be one production order on one press with one coil lot, or a defined period of continuous running.

The choice matters more than it looks. A narrow lot definition means more identifiers to manage, but a defect traced to one coil brackets tightly and only a small quantity of material is implicated. A wide definition is administratively easier and turns any investigation into a large exposure. Because primary packaging is consumed in high volume, the lot definition is effectively a decision about how much material the business is willing to put at risk in a single investigation.

Lot identity also has to survive repacking. If cartons are consolidated, split across shipments, or held in a warehouse for months, the identifier has to remain readable and linked to the original production record.

What has to be traceable

Traceability covers three layers: what went in, what happened during production, and what went out.

Layer	Traced item	Where the link is recorded
Inputs	Aluminium coil lot, with mill certificate	Goods receipt record and incoming inspection release
Inputs	Polymer and colour masterbatch lots	Goods receipt and moulding batch record
Inputs	Lacquer, primer and ink lots	Goods receipt and coating or printing record
Process	Press, mould, tooling set and line	Production order and equipment log
Process	Date, shift and operator	Production order
Process	In-process dimensional checks and inspection results	Inspection records tied to the production order
Process	Deviations, rework and any concession	Deviation and nonconformance records
Outputs	Packed cartons, quantities, and the lot identifier printed on each	Packing record
Outputs	Customer, delivery note and dispatch date	Dispatch record

The chain has to be continuous. A gap anywhere, for example cartons packed without recording which production order filled them, breaks the link and forces any later investigation to assume the widest possible exposure.

The aluminium grade of the incoming coil is a good example of why the input layer matters. Alloy, temper and gauge are agreed per specification and evidenced on a mill certificate per coil, so if a run of seals crimps differently than expected, the coil lot is the first thing an investigation looks at.

Backward and forward traceability

Backward traceability answers “what is in this carton”; forward traceability answers “where did this coil go”. Both are needed, and they are used at different moments.

Backward traceability is the investigation tool. A customer reports a dimensional or cosmetic issue, quotes the lot number on the carton, and the supplier pulls the production order, the inspection results, the coil and polymer lots, the tooling set, and the shift. That reconstruction usually identifies whether the cause is material, tooling, process or handling.

Forward traceability is the containment tool. Once a root cause is attributed to a specific input, the question changes: which other production orders used that coil lot, which cartons did they produce, and which customers received them. That query determines the size of any market action. It is the reason dispatch records have to link lot identifiers to customers rather than just to quantities.

The documentation that travels with a seal lot

A shipment of seals normally arrives with a small, standard document set, and the receiving quality unit builds its own records on top of it.

Certificate of analysis or certificate of conformance, quoting the lot identifier and confirming the lot was made and tested to the agreed specification.
Packing list and lot-marked cartons, so quantities reconcile and identity survives storage.
The agreed technical specification and drawing for the product, held under change control, against which the certificate is read.
A Drug Master File reference, where the supplier holds one. A Type III DMF lets a customer’s US filing reference the supplier’s confidential material and process detail without the supplier disclosing it.
Change notification commitments, the contractual undertaking to notify the customer before a material, process or site change. This is what stops a silent change to a qualified component.
Declarations as applicable to the market, for example on materials of animal origin or on the composition of food-contact and product-contact materials.

None of these replace the customer’s own incoming controls. Under 21 CFR 211.84, each lot of drug product containers and closures is withheld from use until it has been sampled, tested or examined as appropriate and released by the quality control unit.

What the standards require

Two rule sets meet at the seal: the packaging manufacturer’s quality system and the drug manufacturer’s GMP.

On the supplier side, ISO 15378:2017 is the sector standard for primary packaging materials, applying GMP requirements on top of ISO 9001:2015. Its parent standard’s clause 8.5.2 requires organisations to identify outputs and to control and retain the unique identification where traceability is a requirement, and the GMP layer in ISO 15378 is what turns that into batch records, contamination control, validated processes and defined retention.

On the customer side, the relevant obligations sit in 21 CFR Part 211:

211.80 requires a receiving code or identifier for each lot of components, containers and closures.
211.84 requires each lot to be sampled, examined and released by the quality control unit before use.
211.184 requires records including the identity and quantity of each shipment, the supplier’s name and lot number, the receiving code, the date of receipt, test results and conclusions, the disposition of rejected material, and an inventory record with a reconciliation of the use of each lot. The regulation is explicit that the record must hold enough information to determine any batch of drug product associated with the use of each container and closure.

The European framework reaches the same outcome through EU GMP: Chapter 4 on documentation and Chapter 5 on production govern starting and packaging material control, and batch documentation is retained for one year after the batch expires or five years after certification by the Qualified Person, whichever is longer. Retention samples of packaging materials are addressed in Annex 19.

How the seal lot number is used inside a drug batch record

Once released, the seal lot number becomes a data point inside the drug product’s own batch record, which is what closes the loop between a carton of seals and a patient-facing vial. The sequence is straightforward: goods-in assigns a receiving code, quality releases the lot, the warehouse issues a defined quantity to a production order, and the packaging or filling batch record captures which seal lot was used on which filled batch. At the end of the run, quantities issued, used, rejected and returned are reconciled.

That reconciliation is the point. It means a regulator or an investigator can start from a single distributed vial, read its batch number, open the batch record, and arrive at the seal lot, the supplier and the supplier’s own production order. Where a capping problem is suspected, that path also identifies which capping equipment and settings were in use for that batch.

Traceability when something goes wrong

In an investigation, traceability sets the boundary of the problem, and a weak chain forces a conservative and expensive boundary. The sequence usually runs: a defect is detected in incoming inspection, on the capping line, at final inspection, or in the field; the affected lot is quarantined; backward traceability reconstructs how it was made; a root cause is attributed to an input, a process step or handling; forward traceability identifies every other lot and customer exposed to the same cause; and the response is sized accordingly.

The cost difference between a good chain and a poor one shows up here. With coil-level granularity, a metal defect might implicate a few production orders. Without it, the only defensible bracket may be every lot made in the period, which can mean the whole supply to several customers. Investigation records, deviations and the resulting corrective actions become part of the lot history and are reviewed in subsequent audits.

How this works in practice at Autofits

Autofits operates lot-level traceability across its FlipTop aluminium-plastic seals, tear-off and tear-down aluminium seals, and aluminium pilfer-proof (ROPP) caps, all listed on the products page, with each finished lot linked back through packing, inspection, assembly, moulding and stamping to the originating aluminium and polymer lots. Production runs in a 75,000 sq ft Nashik facility with an ISO Class 8 cleanroom, at a scale of around 2.4 billion seals a year, so lot discipline is what keeps that volume investigable. The quality system is certified to ISO 15378:2017 alongside ISO 9001:2015 and ISO 14001:2015, and the company holds a Drug Master File that customers can reference in their own filings. The full certification set is on the quality page.

Frequently asked questions

What is batch traceability for vial seals?

It is the documented ability to link every packed lot of seals back to the aluminium coil, polymer, lacquer and ink lots it was made from, the press, tooling, line and shift that produced it, and the inspection records that released it, and to work forwards from any input lot to every customer that received it. It is required of the packaging manufacturer by ISO 15378:2017 and relied on by the drug manufacturer under GMP.

What records must a drug manufacturer keep for closures?

Under 21 CFR 211.184, records must include the identity and quantity of each shipment of each lot of containers and closures, the supplier’s name and lot number, the receiving code, the date of receipt, test or examination results, the disposition of rejected material, and an inventory record reconciling the use of each lot. The record must contain enough information to determine which batches of drug product used each lot.

What documents come with a lot of vial seals?

Typically a certificate of analysis or conformance quoting the lot identifier, a packing list, lot-marked cartons, and the agreed technical specification the certificate is read against. Where the supplier holds one, a Type III Drug Master File reference lets a customer’s US filing cite the supplier’s confidential detail. A change notification commitment is normally agreed contractually.

How does ISO 15378 address traceability?

ISO 15378:2017 applies GMP requirements to the manufacture of primary packaging materials on top of ISO 9001:2015, whose clause 8.5.2 covers identification and traceability. In practice that means defined batch identification, batch records covering materials and process, retention of records, contamination control, and the ability to reconstruct how any given lot was produced.

How long are packaging batch records kept?

Retention is set by the applicable GMP framework rather than by the packaging supplier alone. Under EU GMP, batch documentation is retained for one year after the batch expires or five years after certification by the Qualified Person, whichever is longer. Suppliers set their own retention periods in the quality system, usually aligned to the longest requirement among the markets they serve.

Why does the size of a batch matter for traceability?

Because the lot is the unit of investigation. A narrow lot definition means a defect brackets to a small quantity of material and a small number of customers. A wide definition makes record-keeping simpler but turns every investigation into a large exposure, since the only defensible boundary is the whole lot.

Sources

ISO: ISO 15378:2017, Primary packaging materials for medicinal products, Particular requirements for the application of ISO 9001:2015, with reference to GMP (https://www.iso.org/standard/70729.html)
eCFR: 21 CFR 211.184, Component, drug product container, closure, and labeling records (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.184)
eCFR: 21 CFR 211.84, Testing and approval or rejection of components, drug product containers, and closures (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-E/section-211.84)
European Commission: EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice, Part I Chapter 4 (Documentation) and Annex 19 (Reference and Retention Samples) (https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en)
FDA: Drug Master Files (https://www.fda.gov/drugs/drug-master-files-dmfs/types-drug-master-files-dmfs)

*Last updated: 2026-07-31. This article is general technical and regulatory information, not legal or compliance advice; confirm current requirements with the relevant regulator and standard.*